TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(2 sites)

United States

The University of Texas MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Center, Seattle, Washington